Cogent Biosciences, Inc. COGT
Set alert
As of Nov 2, 1:03 PM ET
- YTD
- -15.19%
- 1 year
- +84.82%
- Open
- 31.31
- Prev close
- 31.02
- Mkt cap
- 5.23B
- Vol
- 813.81K
- Avg vol
- 2.00M
- EPS
- -2.16
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 29.96
- High
- 31.48
- Forward P/E
- -25.92
- Beta
- 0.31
- Short ratio
- 8.48
- Inst. own
- 115.68%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 6, 2026
- 50-d avg
- 32.51
- 200-d avg
- 35.74
- 1y target
- 55.82
5D chart
Signals (123)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 3:20 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:05 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:00 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:55 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:30 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:20 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 2:20 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 1:45 PM | 3 days ago |
| SMA: Bullish | Oct 30, 1:15 PM | 3 days ago |
| SMA: Bearish | Oct 30, 1:10 PM | 3 days ago |
| SMA: Bullish | Oct 30, 12:55 PM | 3 days ago |
| SMA: Bearish | Oct 30, 12:45 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 12:20 PM | 3 days ago |
| SMA: Bullish | Oct 30, 12:15 PM | 3 days ago |
| RSI: Oversold | Oct 30, 12:00 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 11:35 AM | 3 days ago |
| RSI: Oversold | Oct 30, 11:35 AM | 3 days ago |
| SMA: Bearish | Oct 30, 11:15 AM | 3 days ago |
| MACD: Buy Signal | Oct 30, 10:50 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:40 AM | 3 days ago |
| RSI: Oversold | Oct 30, 10:30 AM | 3 days ago |
| RSI: Oversold | Oct 30, 10:05 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 9:45 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:40 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:40 AM | 3 days ago |
| SMA: Bullish | Oct 30, 9:35 AM | 3 days ago |
| SMA: Bullish | Oct 30, 9:35 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 3:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:35 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:10 PM | 3 days ago |
| RSI: Oversold | Oct 29, 2:15 PM | 3 days ago |
| RSI: Oversold | Oct 29, 1:55 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 1:45 PM | 4 days ago |
| SMA: Bearish | Oct 29, 1:30 PM | 4 days ago |
| SMA: Bullish | Oct 29, 1:15 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 1:10 PM | 4 days ago |
| SMA: Bearish | Oct 29, 11:30 AM | 4 days ago |
| SMA: Bullish | Oct 29, 11:10 AM | 4 days ago |
| SMA: Bullish | Oct 29, 11:05 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:50 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 10:35 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:30 AM | 4 days ago |
| SMA: Bullish | Oct 29, 10:15 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 4 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 28, 3:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:10 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:25 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:45 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 1:45 PM | 5 days ago |
| SMA: Bearish | Oct 28, 1:35 PM | 5 days ago |
| SMA: Bullish | Oct 28, 1:30 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 1:30 PM | 5 days ago |
| SMA: Bullish | Oct 28, 1:05 PM | 5 days ago |
| SMA: Bearish | Oct 28, 12:15 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 11:45 AM | 5 days ago |
| SMA: Bearish | Oct 28, 11:40 AM | 5 days ago |
| RSI: Overbought | Oct 28, 11:20 AM | 5 days ago |
| SMA: Bullish | Oct 28, 11:15 AM | 5 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 5 days ago |
| RSI: Overbought | Oct 28, 10:45 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 10:25 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:20 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:10 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:05 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:15 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:10 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:05 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 6 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 6 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 6 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 6 days ago |
| SMA: Bearish | Oct 27, 12:05 PM | 6 days ago |
| RSI: Overbought | Oct 27, 11:55 AM | 6 days ago |
| MACD: Sell Signal | Oct 27, 11:40 AM | 6 days ago |
| RSI: Overbought | Oct 27, 11:35 AM | 6 days ago |
| RSI: Overbought | Oct 27, 11:25 AM | 6 days ago |
| RSI: Overbought | Oct 27, 10:45 AM | 6 days ago |
| SMA: Bullish | Oct 27, 9:50 AM | 6 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 6 days ago |
| RSI: Overbought | Oct 27, 9:40 AM | 6 days ago |
| SMA: Bullish | Oct 27, 9:35 AM | 6 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 6 days ago |
| SMA: Bullish | Oct 26, 3:15 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:15 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:45 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:35 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:30 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:25 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:15 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:05 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 2:05 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:20 PM | 1 week ago |
| MACD: Sell Signal | Oct 26, 12:45 PM | 1 week ago |
| SMA: Bearish | Oct 26, 12:25 PM | 1 week ago |
| SMA: Bearish | Oct 26, 12:25 PM | 1 week ago |
| SMA: Bullish | Oct 26, 12:15 PM | 1 week ago |
| SMA: Bullish | Oct 26, 12:15 PM | 1 week ago |
| SMA: Bearish | Oct 26, 12:05 PM | 1 week ago |
| SMA: Bearish | Oct 26, 12:05 PM | 1 week ago |
| SMA: Bullish | Oct 26, 12:00 PM | 1 week ago |
| SMA: Bullish | Oct 26, 12:00 PM | 1 week ago |
| SMA: Bearish | Oct 26, 11:55 AM | 1 week ago |
| SMA: Bullish | Oct 26, 11:50 AM | 1 week ago |
| SMA: Bearish | Oct 26, 11:30 AM | 1 week ago |
| SMA: Bearish | Oct 26, 10:55 AM | 1 week ago |
| SMA: Bullish | Oct 26, 10:50 AM | 1 week ago |
News
5 days ago globenewswire.com
Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference
WALTHAM, Mass. and BOULDER, Colo.
1 week ago benzinga.com
If You Invested $1000 In Cogent Biosciences Stock 5 Years Ago, You Would Have This Much Today
Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past 5 years by 19.53% on an annualized basis producing an average annual return of 30.65%. Currently, Cogent Biosciences has a…
-
2 weeks ago benzinga.com
Here’s How Much You Would Have Made Owning Cogent Biosciences Stock In The Last 5 Years
Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past 5 years by 14.59% on an annualized basis producing an average annual return of 26.37%. Currently, Cogent Biosciences has a…
1 month ago benzinga.com
$1000 Invested In Cogent Biosciences 5 Years Ago Would Be Worth This Much Today
Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past 5 years by 16.44% on an annualized basis producing an average annual return of 28.63%. Currently, Cogent Biosciences has a…
1 month ago defenseworld.net
Cogent Biosciences, Inc. (NASDAQ:COGT) Stock Has Consensus Price Target of $51.56
Cogent Biosciences, Inc. (NASDAQ: COGT - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the twelve ratings firms that are presently covering the company, Marketbeat…
-
1 month ago benzinga.com
Here’s How Much You Would Have Made Owning Cogent Biosciences Stock In The Last 5 Years
Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past 5 years by 18.64% on an annualized basis producing an average annual return of 30.55%. Currently, Cogent Biosciences has a…
-
1 month ago benzinga.com
Wedbush Reiterates Outperform on Cogent Biosciences, Maintains $55 Price Target
Wedbush analyst David Nierengarten reiterates Cogent Biosciences (NASDAQ:COGT) with a Outperform and maintains $55 price target.
-
1 month ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Cogent Biosciences, Maintains $55 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Cogent Biosciences (NASDAQ:COGT) with a Buy and maintains $55 price target.
-
1 month ago benzinga.com
FDA Accepts Cogent Biosciences' NDA For Bezuclastinib In Patients With Advanced Systemic Mastocytosis
NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSMPDUFA target action date set for…
1 month ago globenewswire.com
Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM
-
2 months ago benzinga.com
Cogent Biosciences Enters Commercial Supply Agreement With Hovione On Sept 1, 2026; To Purchase Minimum Percentages Of Bezuclastinib Products From Hovione; Agreement Effective For Five-Year Term With Automatic Two-Year Renewals
On September 1, 2026, Cogent Biosciences, Inc. (the "Company") entered into a Commercial Supply Agreement (the "Agreement") with Hovione FarmaCiencia S.A. ("Hovione") to manufacture bezuclastinib
-
2 months ago benzinga.com
$100 Invested In Cogent Biosciences 5 Years Ago Would Be Worth This Much Today
Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past 5 years by 22.44% on an annualized basis producing an average annual return of 33.55%. Currently, Cogent Biosciences has a…
2 months ago seekingalpha.com
Cogent Biosciences: 3 NDAs Create A Time-To-Market Moat
Cogent Biosciences is positioned to commercialize bezuclastinib across three indications, leveraging a single precision molecule for multi-market entry. Positive pivotal data in GIST, NonAdvSM, and…
2 months ago defenseworld.net
Deutsche Bank AG Takes $10.32 Million Position in Cogent Biosciences, Inc. $COGT
Deutsche Bank AG acquired a new stake in shares of Cogent Biosciences, Inc. (NASDAQ: COGT) during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The…
2 months ago defenseworld.net
Handelsbanken Fonder AB Purchases New Stake in Cogent Biosciences, Inc. $COGT
Handelsbanken Fonder AB acquired a new position in shares of Cogent Biosciences, Inc. (NASDAQ: COGT) during the second quarter, according to the company in its most recent filing with the Securities…
-
2 months ago benzinga.com
Piper Sandler Maintains Overweight on Cogent Biosciences, Raises Price Target to $55
Piper Sandler analyst Christopher Raymond maintains Cogent Biosciences (NASDAQ:COGT) with a Overweight and raises the price target from $52 to $55.
2 months ago zacks.com
Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Cogent Biosciences (COGT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions…
-
2 months ago benzinga.com
Guggenheim Maintains Buy on Cogent Biosciences, Raises Price Target to $52
Guggenheim analyst Michael Schmidt maintains Cogent Biosciences (NASDAQ:COGT) with a Buy and raises the price target from $45 to $52.
-
2 months ago benzinga.com
Cogent Biosciences Files Prospectus for At-The-Market Offering Of Up To $400M In Common Stock
Up to $400,000,000COMMON STOCKWe have entered into a Sales Agreement with Guggenheim Securities, LLC ("Guggenheim Securities"), dated May 6, 2022, as amended by that certain Amendment No. 1 to Sales…
-
2 months ago benzinga.com
Cogent Biosciences Q2 EPS $(0.52) Beats $(0.57) Estimate
Cogent Biosciences (NASDAQ:COGT) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.57) by 8.77 percent. This is a 1.89 percent increase over losses of…
2 months ago globenewswire.com
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results
On track for potential approval of bezuclastinib for GIST patients (PDUFA November 30) and NonAdvSM patients (PDUFA December 30) later this year; AdvSM New Drug Application submitted to FDA on June…
-
2 months ago benzinga.com
If You Invested $100 In Cogent Biosciences Stock 5 Years Ago, You Would Have This Much Today
Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past 5 years by 28.96% on an annualized basis producing an average annual return of 40.76%. Currently, Cogent Biosciences has a…
-
4 months ago benzinga.com
Cogent Biosciences Files New Drug Application To FDA For Bezuclastinib In Advanced Systemic Mastocytosis
Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced it has submitted its New Drug Application…
4 months ago globenewswire.com
Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)
Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated…
4 months ago seekingalpha.com
Cogent Biosciences: A Pre-Commercial Biotech With Commercial-Stage Leverage
Cogent Biosciences is positioned to build a niche KIT-mutant franchise, leveraging bezuclastinib across three pivotal indications with strong clinical data. COGT holds $866.4 million in cash,…
-
4 months ago benzinga.com
Cogent Biosciences To Present Preclinical Data From Its Novel JAK2 V617F Mutant-Selective Inhibitor At The 2026 European Hematology Association Congress, June 11-14
We're encouraged by the preclinical data from our next-generation JAK2 program being presented at EHA today," said Andrew Robbins, Cogent's President and Chief Executive Officer. "This highly…
4 months ago globenewswire.com
Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress
- JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors -
4 months ago globenewswire.com
Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress
-- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an updated objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria –
5 months ago globenewswire.com
Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16. 5 months versus 9. 2 months (HR=0.…
-
5 months ago benzinga.com
Wedbush Reiterates Outperform on Cogent Biosciences, Maintains $55 Price Target
Wedbush analyst David Nierengarten reiterates Cogent Biosciences (NASDAQ:COGT) with a Outperform and maintains $55 price target.
-
5 months ago benzinga.com
Cogent Biosciences Says FDA Accepts NDA For Bezuclastinib In Combination With Sunitinib For Patients With GIST With PDUFA Target Action Date Of November 30
NDA acceptance with Priority Review builds upon previous assignment of Breakthrough Therapy Designation and Real-Time Oncology Review following Phase 3 PEAK results; PDUFA date set for November 30,
5 months ago globenewswire.com
Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST
NDA acceptance with Priority Review builds upon previous assignment of Breakthrough Therapy Designation and Real-Time Oncology Review following Phase 3 PEAK results; PDUFA date set for November 30,…
5 months ago globenewswire.com
Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference
WALTHAM, Mass. and BOULDER, Colo.
5 months ago globenewswire.com
Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress
WALTHAM, Mass. and BOULDER, Colo., May 12, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined…
-
6 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Cogent Biosciences, Raises Price Target to $55
HC Wainwright & Co. analyst Robert Burns maintains Cogent Biosciences (NASDAQ:COGT) with a Buy and raises the price target from $52 to $55.
-
6 months ago benzinga.com
Cogent Biosciences Q1 EPS $(0.53) Beats $(0.56) Estimate
Cogent Biosciences (NASDAQ:COGT) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(0.56) by 5.36 percent. This is a 1.92 percent decrease over losses of…
6 months ago globenewswire.com
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results
- Planning for dual launches of bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST) - Pivotal data from Phase 3 PEAK trial in GIST patients selected for oral…
6 months ago globenewswire.com
Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
WALTHAM, Mass. and BOULDER, Colo.
-
6 months ago benzinga.com
Cogent Biosciences Announces Poster Presentations Of Preclinical Data From The KRAS And ErbB2 Pipeline Programs At The American Association For Cancer Research Meeting, April 17-22
Poster DetailsTitle: Characterization of CGT1263, a KRAS (ON/OFF) inhibitor clinical candidate with selectivity for mutant KRAS over HRAS and NRASSession Category: Experimental and Molecular…
6 months ago globenewswire.com
Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
– Updated presentation on Cogent's potent pan-KRAS(ON) inhibitor, CGT1263, showcasing its selectivity profile which could lead to reduction in skin toxicity associated with multi-RAS inhibitors
-
7 months ago benzinga.com
Cogent Biosciences Files New Drug Application To FDA For Bezuclastinib In Patients With Gastrointestinal Stromal Tumors
Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the completion of the submission of its…
-
7 months ago benzinga.com
Wedbush Reiterates Outperform on Cogent Biosciences, Maintains $55 Price Target
Wedbush analyst David Nierengarten reiterates Cogent Biosciences (NASDAQ:COGT) with a Outperform and maintains $55 price target.
7 months ago benzinga.com
Cogent Biosciences Stock Climbs After FDA Accepts Key Drug Application
FDA accepts Cogent Biosciences' NDA for bezuclastinib in NonAdvSM. PDUFA date set for Dec 30, 2026. COGT stock rises on the news.
-
8 months ago benzinga.com
Reported Saturday, Cogent Biosciences Highlights SUMMIT Data At AAAAI 2026, Bezuclastinib Delivers –32.0 Point Mean TSS Reduction At 48 Weeks With 99% Achieving ≥50% Serum Tryptase Reduction
Bezuclastinib mean TSS reduction deepens to –32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms99% of patients achieve >50% reduction in serum tryptase…
-
8 months ago benzinga.com
Piper Sandler Maintains Overweight on Cogent Biosciences, Raises Price Target to $52
Piper Sandler analyst Christopher Raymond maintains Cogent Biosciences (NASDAQ:COGT) with a Overweight and raises the price target from $39 to $52.
-
8 months ago benzinga.com
Cogent Biosciences Q4 EPS $(0.61) Misses $(0.53) Estimate
Cogent Biosciences (NASDAQ:COGT) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.53) by 15.97 percent. This is a 577.78 percent decrease over losses…
9 months ago benzinga.com
Why Is Pfizer Stock Rising Tuesday?
Pfizer Inc. (PFE) shares are trading higher on Tuesday, as the stock benefits from a price target increase at Cantor Fitzgerald. The firm raised its target to $27 from $24, providing a catalyst for…
9 months ago benzinga.com
Cogent's New Stomach Cancer Treatment Cuts Progression Risk In Half, Gets Breakthrough Therapy Tag
The FDA granted breakthrough status to Cogent's GIST drug combo after a trial showed it cut disease progression or death risk by 50% compared with current treatment.
-
9 months ago benzinga.com
The FDA Grants Breakthrough Therapy Designation To Cogent Biosciences' Bezuclastinib Plus Sunitinib For Gastrointestinal Stromal Tumor Patients Previously Treated With Imatinib
This Breakthrough Therapy Designation is based on results from the PEAK trial which demonstrated a substantial and highly statistically significant clinical benefit on the primary endpoint of…
-
9 months ago benzinga.com
Wedbush Reiterates Outperform on Cogent Biosciences, Maintains $55 Price Target
Wedbush analyst David Nierengarten reiterates Cogent Biosciences (NASDAQ:COGT) with a Outperform and maintains $55 price target.